Celcuity Inc. – Filings and Transcripts

NASDAQ: CELC
Share price (9/30/26): $79.52
Market cap (9/30/26): $3.891 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Free writing prospectus

Prospectus supplement for primary offering

Registration of securities for employees

Automatic shelf registration

Ownership Filter

Sullivan Brian F.

Bank of America Corporation

Baker Julian, Baker Felix, Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC

News Filter

Announces That REVTORPYK™ (Gedatolisib) Is Now Commercially Available in the United States

Submits sNDA to FDA for REVTORPYK™ (Gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

Announces FDA Approval of REVTORPYK™ (Gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

Announces FDA Approval of REVTORPYK™ (Gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Statement of eligibility as a trustee

Scanned paper annual report submission

Statement of eligibility as a trustee

Scanned paper annual report submission

Notice of effectiveness